Press Room

On July 9th, 2022, the Government of the Special Administrative Region of Macau issued the Executive Order No. 115/2022 ordering all industries and commercial businesses located in Macau to suspend operations and shut down from July 11th to July 18th as an extraordinary measure to contain the spread of COVID-19 in the community. In accordance with the executive order, the majority of businesses located in Macau are obliged to shut down from 00:00 on July 11th, 2022 to 00:00 on July 23rd, 2022, including 四色AV's manufacturing facility located in the territory.    Since the start of the COVID-19 epidemic, 四色AV has been employing procedures and rules to reduce and minimize the impact of forced shutdowns and closures to our manufacturing facilities. Although the temporary suspension of our activities in Macau is beyond the reasonable control of 四色AV and mandated by the local government, we will continue to employ all measures to reduce and mitigate the impact of such Interruption on our activities, our customers and partners.    Some of the measures employed at this facility include building up safety stocks of raw materials and finished API, advancing shipment dispatch dates to those clients facing the highest risk of disruption, leveraging bonded warehouses to allow for continued supply of materials, among others.    We commit to immediately notifying you if there are any foreseeable disruptions that may impact your product. Should you have any questions feel free to reach out to your account manager who will be happy to support you.    In the meantime, we will continue to make safe our place of work in order to continue serving our clients and our communities the best we can as we are In it for life.           About 四色AV 四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of and services, from API, formulation development and devices. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.        Find more about our site, 四色AV Macau          

News
News release, 18 July 2022

Communication of Site Shutdown - 四色AV Macau

Jul 18, 2022

Video - We are the Second Line of Defense To watch the video with subtitles, choose your language:  PT  |  CN  |  EN   English     SARS-CoV-2: What & How Question: What is a virus? Answer: A virus is not a bacteria. A virus is a microorganism that causes damage in the body by invading cells (these cells are called hosts). Unlike bacteria, all viruses cause disease.   Question: What is the difference between a virus and a bacterium? Answer: Both bacteria and viruses are microorganisms. But think of it this way: an elephant and a rat are completely different but they鈥檙e both animals. Same goes for the virus and bacteria. Additionally, one of the biggest differences between bacteria and viruses, is their size. A bacterium is the size of a large orange, in comparison to a virus which would be the size of an apple seed.   Question: How is Covid-19 transmitted? Answer: The main route of transmission is through respiratory droplets. We expel these when we sneeze, cough or even when we talk! Another common route includes touching surfaces that have the virus and then touching your face (before washing your hands). Find more in this article published in Elsevier   Question: Can a virus live on non-living surfaces? Answer: Yes. Although viruses live off of other organisms, such as animals or plants, they can be found on non-living surfaces. However, a virus cannot survive for a very long time on non-living surfaces. Find more on The New England Journal of Medicine   Question: How long does the virus last on surfaces? Answer:      Food: no evidence to suggest it spreads through food Paper: from a few minutes up to 5 days Cardboard: ~ 24 hours Wood: ~ 4 days Plastic: ~ 2/3 days Metals:  ~ 5 days Steel: ~ 2/3 days   The overall survival rate of the virus on surfaces may vary slightly according to the amount of sunlight and humidity the virus gets exposed to. Find more on The New England Journal of Medicine   Question: Will warm weather stop the outbreak of Covid-19? Answer: It is not yet known whether weather and temperature affect the spread of Covid-19. Some other viruses, like those that cause the common cold and flu, spread more during cold weather months but that does not mean it is impossible to become sick with these viruses during other months.  There is much more to learn about the transmissibility, severity, and other features associated with Covid-19 and investigations are ongoing. Find more at CDC.gov   Question: Can someone who has been quarantined for Covid-19 spread the illness to others? Answer: Quarantine means separating a person or group of people who have been exposed to a contagious disease but have not developed illness (symptoms) from others who have not been exposed, in order to prevent the possible spread of that disease. Quarantine is usually established for the incubation period of the communicable disease, which is the span of time during which people have developed illness after exposure. For Covid-19, the period of quarantine is 14 days from the last date of exposure because the incubation period for this virus is 2 to 14 days. Someone who has been released from Covid-19 quarantine is not considered a risk for spreading the virus to others because they have not developed illness during the incubation period. Find more at CDC.gov   Question: How does Covid-19 affect our cells? Answer: Covid-19 is particularly good at sticking to respiratory tissue. This means attaching to cells found mainly in the lungs. The virus does this by using its crown-like spikes which are attached to the virus鈥 envelope. As a result, one virus particle can attach itself to multiple cells in the body.       The easiest paths of entry for the virus are the mouth, nose and eyes. Once the virus manages to attach itself to the host cell, the host cell will take the virus particle in. The virus will then release genetic information called RNA. RNA acts as a set of instructions that tells the host cell what to do. Therefore, RNA will stop a cell from functioning normally, and instead will convert the healthy host cell into a virus making factory. Once the new virus is assembled inside the host cell, it is released into the surroundings, hence causing even further infection in the body. If our immune system is not effective at fighting the virus and stopping it from spreading onto further cells, more virus-making factories are created in our body using our cells. This eventually kills the host cell, as it is starved by the virus, causing us to have severe respiratory problems, amongst other consequences.   Question: Why do we need to use facemasks? Answer: Facemasks reduce the distance respiratory particles can travel. This means that it reduces the chances of getting infected by preventing the spread of respiratory droplets. It also acts as a filter to the air you breath in and so prevents you from inhaling the virus. Find more at CDC.gov   Question: How does washing our hands with soap, get rid of the virus? Answer: Soap is crucial as it contains chemicals that break down the layer of fat surrounding the coronavirus (envelope) and hence completely destroy it. Using only water doesn鈥檛 help because it doesn鈥檛 stop the virus from sticking to your hand. Watch this video to learn how soap kills the coronavirus   Question: Why should you avoid touching your face? Answer: This is because the virus can easily enter the body through the mouth, nose or even eyes. However, the virus doesn鈥檛 enter your body through the skin, as this acts as a physical barrier.  Find more at CDC.gov   Question: Should I take antibiotics to treat Covid-19 and are anti-bacterial products useful? Answer: Antibiotics are not designed to stop viral infections and therefore are of no use when trying to treat Covid-19. As explained above, bacteria and viruses are two very different microorganisms. This means that anti-bacterial products are not useful either, for when disinfecting surfaces from Covid-19. Instead you should use disinfectant or alcohol.   Question: Is the virus鈥 ability to spread affected by the climate? Answer: So far there is no scientific evidence to suggest or prove that the virus is less effective at spreading in hot or humid weather.   Question: What are the symptoms of Covid-19? Answer:  People with Covid-19 have had a wide range of symptoms reported 鈥 ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have Covid-19: Fever or chills Cough Shortness of breath or difficulty breathing Fatigue Muscle or body aches Headache New loss of taste or smell Sore throat Congestion or runny nose Nausea or vomiting Diarrhea This list does not include all possible symptoms. CDC will continue to update this list as we learn more about Covid-19. Find more at CDC.gov   Question: Can someone test negative and later positive on a viral test for Covid-19? Answer:  Yes, it is possible. You may test negative if the sample was collected early in your infection and test positive later during this illness. You could also be exposed immune to Covid-19 after the test and get infected then. Even if you test negative, you still should take steps to鈥痯rotect yourself and others. See Testing for Current Infection for more information. Find more at CDC.gov   Question: If I have recovered from Covid-19, will I be immune to it? Answer: We do not know yet if people who recover from Covid-19 can get infected again. CDC and partners are investigating to determine if a person can get sick with Covid-19 more than once. Until we know more, continue to take steps to protect yourself and others. Find more at CDC.gov   Question: Who is at higher risk for serious illness from Covid-19? Answer: COVID-19 is a new disease and there is limited information regarding risk factors for severe disease. Based on currently available information and clinical expertise, older adults and people of any age who have serious underlying medical conditions might be at higher risk for severe illness from Covid-19. Based on what we know now, those at high-risk for severe illness from Covid-19 are: People aged 65 years and older People who live in a nursing home or long-term care facility People of all ages with underlying medical conditions, particularly if not well controlled, including: People with chronic lung disease or moderate to severe asthma People who have serious heart conditions People who are immunocompromised Many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV or AIDS, and prolonged use of corticosteroids and other immune weakening medications People with severe obesity (body mass index [BMI] 鈮40) People with diabetes People with chronic kidney disease undergoing dialysis People with liver disease Find more at CDC.gov   Question: What should people at higher risk of serious illness with Covid-19 do? Answer: If you are at higher risk of getting very sick from Covid-19, you should: Stock up on supplies Take everyday precautions to keep space between yourself and others When you go out in public, keep away from others who are sick Limit close contact and wash your hands often Avoid crowds, cruise travel, and non-essential travel If there is an outbreak in your community, stay home as much as possible. Watch for symptoms and emergency signs. If you get sick, stay home and call your doctor. More information on how to prepare, what to do if you get sick, and how communities and caregivers can support those at higher risk is available on People at Risk for Serious Illness from COVID-19. Find more at CDC.gov   Useful links httpss://www.youtube.com/watch?v=O-3Mlj3MQ_Q&feature=youtu.be httpss://www.youtube.com/watch?v=n6QwnzbRUyA&feature=youtu.be httpss://www.livescience.com/coronavirus-kids-guide.html httpss://www.natgeokids.com/au/discover/science/general-science/what-is-coronavirus/ httpss://www.youtube.com/watch?v=BE-cA4UK07c&feature=youtu.be httpss://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/fulltext httpss://www.wjgnet.com/2307-8960/full/v8/i8/1391.htm   Relevant Information 四色AV Practical Handbook - Covid-19 The Coronavirus Prevention Handbook Spanish Flu book chapter Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition) At the time this was the best informed source on the Novel Coronavirus is probably PRC鈥檚 Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition). This is an unofficial google translated version of the document (6th version) Report from WHO panel of international experts that just returned from a fact-finding mission to China 鈥 (25 February 2020) WHO-2019-nCoV-IPC - Water, sanitation, hygiene, and waste management for the COVID-19 virus EN - The WHO informs that in order to sanitize surface areas you can use a mixture of 0,5% of bleach (sodium hypochlorite) in water. Bleach bottles for household use indicate the concentration percentage in their labels - a bottle from Continente supermarket, for instance, indicates 5% - therefore to use this product to sanitize an area you need to dissolve it in water - one measuring cup of bleach for nine measuring cups of water will provide you with a solution containing 0,5% bleach. Be extremely careful when handling bleach with a 5% concentration. It can burn the skin. If it spills drops to the skin or eyes wash them immediately with abundant water for two minutes.  WHO-recommended Handrub Formulations   Rate of growth of COVID-19 SARS-Cov-2 Report - 30 November 2021   四色AV Crisis Response COVID-19 - 四色AV Crisis Response COVID-19 Preparedness Response - Countermeasures adopted prior to Chinese New Year at the 四色AV Macau plant    Stakeholders Communiqu茅s Communication of Site Shutdown - 四色AV Macau 15 July 2022 16th Stakeholder Communiqu茅 Covid-19 11 May 2021 15th Stakeholder Communiqu茅 Covid-19 12 March 2021 14th Stakeholder Communiqu茅 Covid-19 5 February 2021 13th Stakeholder Communiqu茅 Covid-19 12 January 2021 12th Stakeholder Communiqu茅 Covid-19 7 December 2020 11th Stakeholder Communiqu茅 Covid-19 5 November 2020 10th Stakeholder Communiqu茅 Covid-19 8 October 2020 9th Stakeholder Communiqu茅 - Covid-19 2 September 2020 8th Stakeholder Communiqu茅 - Covid-19 12 August 2020 7th External Stakeholder Communiqu茅 - Covid-19 9 July 2020 6th External Stakeholder Communiqu茅 - Covid-19 8 June 2020 5th External Stakeholder Communiqu茅 - Covid-19 6 May 2020 Covid-19 FAQ 20 April 2020 4th External Stakeholder Communiqu茅 - Covid-19 3 April 2020 Covid-19 - An update from 四色AV's CEO 20 March 2020 3rd External Stakeholder Communiqu茅 - Covid-19 13 March 2020 2nd External Stakeholder Communiqu茅 - Covid-19 12 February 2020 1st External Stakeholder Communiqu茅 - Coronavirus 2019-NCoV 31 January 2020   Webinar   Webinar Presentation Sharing our Covid-19 experience. Seeking Feedback 14 July 2020     Service Providers and External Visitors Guidance Protocol for External Visitors   Contingency Plan - Covid-19   Videos We are the Second Line of Defense (27 April 2020) To watch the video with subtitles, choose your language:  PT  |  CN  |  EN   Message from 脡lie Vannier, Chairman of the Board of Directors (30 July 2020) Language: English and subtitles in Portuguese   Return From Home Rules (7 July 2020)   Message from Filipe Gaspar, Chief Technology Officer (7 April 2020) Language: Portuguese and subtitles in English     Message from Tiago Ferreira de Matos, General Counsel (31 March 2020) Language: Portuguese and subtitles in English     Guy Villax message - Washing hands (25 March 2020)     Message from Eddy Leong, Site Manager - Macao (23 March 2020) What can people do to protect themselves and others from getting the new coronavirus Source: WHO, World Health Organization   WHO: How to handwash? With soap and water Source: WHO, World Health Organization Can masks protect against the new coronavirus infection? Source: WHO, World Health Organization     Certifications     As a result of a joint effort between 四色AV and Gertal, Sete Casas and Lumiar Canteens have been certified by APCER with the 鈥淐ovid Safe Verified鈥 seal. 鈥淐ovid Safe鈥 is a brand developed by APCER that certifies compliance with the new health and safety rules, in the context of the Covid-19 pandemic. This certification is the recognition of the concern of both 四色AV and Gertal in complying with the rules established and providing the best safety conditions for our Team Members.     ABC Covid-19 (for schools) ABC Covid-19 initiative aims to help schools across the country in their return to classes in a practical, direct, and efficient way, by providing support to answer the various difficulties they face in their daily routines. The team is composed of trainees and is supervised by the Covid-19 prevention team at 四色AV and their aim is to inform students about what are good habits to adopt and how to prevent risks while also supporting teachers and staff with up-to-date, reliable and clear information. Here you can find all the information provided in a poster format that you can distribute throughout the school. Portuguese only. Posters 01. Uso de M谩scara A / Uso de M谩scara 02. Uso de M谩scara B  03. Retirar a M谩scara 04. Regras para sair de casa 05. Recomenda莽玫es 06. Prote莽茫o Covid-19 07. Lave as m茫os com frequ锚ncia 08. Lavagem de m茫os / Lavagem de m茫os 09. Lavagem de m茫os com gel desinfetante 10. Como medir a temperatura 11. Medidas Gerais 12. Medidas Escolas 13. Utiliza莽茫o de L铆xivia (1) 14. Utiliza莽茫o de L铆xivia (2) 15. Instru莽玫es para Elevadores 16. Distanciamento Social 17. Desinfetar Superf铆cies     Follow us:               17-year arts student wins ABCovid contest Tom谩s Oliveira, aged 17, from Escola Art铆stica Ant贸nio Arroio, with the video "Covid-19 simplified for morons", which explains simply and graphically why we need a mask to protect ourselves from this virus. The ABCovid contest is an initiative taken by 四色AV trainees aimed at elementary and high school students. For more details visit www.abcovid.pt           Portugu锚s   SARS-CoV-2: O Qu锚 & Como Pergunta: O que 茅 um v铆rus? Resposta: Um v铆rus n茫o 茅 uma bact茅ria. Um v铆rus 茅 um microrganismo que causa danos ao organismo, invadindo as c茅lulas (essas c茅lulas s茫o chamadas de hospedeiros). Ao contr谩rio das bact茅rias, todos os v铆rus causam doen莽as.   Pergunta: Qual 茅 a diferen莽a entre um v铆rus e uma bact茅ria? Resposta: Bact茅rias e v铆rus s茫o microrganismos. Mas pense assim: um elefante e um rato s茫o completamente diferentes, mas ambos s茫o animais. O mesmo vale para o v铆rus e as bact茅rias. Al茅m disso, uma das maiores diferen莽as entre bact茅rias e v铆rus 茅 o seu tamanho. Uma bact茅ria 茅 do tamanho de uma laranja grande, em compara莽茫o com um v铆rus do tamanho de uma semente de ma莽茫.   Pergunta: Como o Covid-19 茅 transmitido? Resposta: A principal via de transmiss茫o 茅 atrav茅s de got铆culas respirat贸rias. N贸s os expulsamos quando espirramos, tossimos ou mesmo quando conversamos! Outra rota comum inclui tocar em superf铆cies com o v铆rus e depois tocar em seu rosto (antes de lavar as m茫os). Saiba mais neste artigo cient铆fico publicado na Elsevier   Pergunta: Um v铆rus pode viver em superf铆cies n茫o-vivas? Resposta: Sim. Embora os v铆rus vivam de outros organismos, como animais ou plantas, eles podem ser encontrados em superf铆cies n茫o-vivas. No entanto, um v铆rus n茫o pode sobreviver por muito tempo em superf铆cies n茫o-vivas. Saiba mais neste artigo publicado na The New England Journal of Medicine   Pergunta: Quanto tempo dura o v铆rus nas superf铆cies? Resposta: Comida: nenhuma evid锚ncia para sugerir que ela se espalha atrav茅s da comida Papel: de alguns minutos a 5 dias Papel茫o: ~ 24 horas Madeira: ~ 4 dias Pl谩stico: ~ 2/3 dias Metais: ~ 5 dias A莽o: ~ 2/3 dias A taxa geral de sobreviv锚ncia do v铆rus nas superf铆cies pode variar ligeiramente de acordo com a quantidade de luz solar e umidade 脿 qual o v铆rus 茅 exposto. Saiba mais neste artigo publicado na The New England Journal of Medicine   Pergunta: O tempo quente vai parar o surto de Covid-19? Resposta: Ainda n茫o se sabe se o clima e a temperatura afetam a propaga莽茫o do Covid-19. Alguns outros v铆rus, como os que causam o resfriado e a gripe comuns, se espalham mais durante os meses de clima frio, mas isso n茫o significa que 茅 imposs铆vel ficar doente com esses v铆rus durante outros meses. H谩 muito mais para aprender sobre a transmissibilidade, a gravidade e outros recursos associados ao Covid-19 e 脿s investiga莽玫es em andamento. Saiba mais no website CDC.gov    Pergunta: Algu茅m que foi colocado em quarentena por Covid-19 pode espalhar a doen莽a para outras pessoas? Resposta: Quarentena significa separar uma pessoa ou grupo de pessoas que foram expostas a uma doen莽a contagiosa, mas n茫o desenvolveram doen莽as (sintomas) de outras que n茫o foram expostas, a fim de impedir a poss铆vel propaga莽茫o dessa doen莽a. A quarentena 茅 geralmente estabelecida para o per铆odo de incuba莽茫o da doen莽a transmiss铆vel, que 茅 o per铆odo durante o qual as pessoas desenvolvem doen莽as ap贸s a exposi莽茫o. Para o COVID-19, o per铆odo de quarentena 茅 de 14 dias a partir da 煤ltima data de exposi莽茫o, porque o per铆odo de incuba莽茫o desse v铆rus 茅 de 2 a 14 dias. Algu茅m que foi liberado da quarentena de COVID-19 n茫o 茅 considerado um risco de espalhar o v铆rus para outras pessoas porque n茫o desenvolveram doen莽as durante o per铆odo de incuba莽茫o. Saiba mais no website CDC.gov   Pergunta: Como o Covid-19 afeta as nossas c茅lulas? Resposta: O Covid-19 茅 particularmente bom em aderir ao tecido respirat贸rio. Isso significa anexar 脿s c茅lulas encontradas principalmente nos pulm玫es. O v铆rus faz isso usando seus picos em forma de coroa, anexados ao envelope do v铆rus. Como resultado, uma part铆cula de v铆rus pode se conectar a v谩rias c茅lulas do corpo. Os caminhos mais f谩ceis de entrada para o v铆rus s茫o a boca, nariz e olhos. Uma vez que o v铆rus consiga se conectar 脿 c茅lula hospedeira, a c茅lula hospedeira absorve a part铆cula do v铆rus. O v铆rus libera informa莽玫es gen茅ticas chamadas RNA. O RNA atua como um conjunto de instru莽玫es que informa 脿 c茅lula hospedeira o que fazer. Portanto, o RNA interrompe o funcionamento normal da c茅lula e, em vez disso, converte a c茅lula hospedeira saud谩vel em uma f谩brica de cria莽茫o de v铆rus. Uma vez que o novo v铆rus 茅 montado dentro da c茅lula hospedeira, ele 茅 liberado para o ambiente, causando ainda mais infec莽玫es no organismo. Se nosso sistema imunol贸gico n茫o 茅 eficaz no combate ao v铆rus e impede que ele se espalhe para outras c茅lulas, mais f谩bricas de cria莽茫o de v铆rus s茫o criadas em nosso corpo, usando nossas c茅lulas. Isso acaba matando a c茅lula hospedeira, pois ela sofre de fome pelo v铆rus, causando problemas respirat贸rios graves, entre outras consequ锚ncias.     Pergunta: Por que precisamos usar m谩scaras? Resposta: As m谩scaras faciais reduzem a dist芒ncia que as part铆culas respirat贸rias podem percorrer. Isso significa que reduz as chances de ser infectado, impedindo a propaga莽茫o de got铆culas respirat贸rias. Tamb茅m atua como um filtro para o ar que voc锚 respira e impede a inala莽茫o do v铆rus. Saiba mais no website CDC.gov   Pergunta: Como lavar as m茫os com sab茫o elimina o v铆rus? Resposta: O sab茫o 茅 crucial, pois cont茅m produtos qu铆micos que quebram a camada de gordura ao redor do coronav铆rus (envelope) e, portanto, o destroem completamente. Usar apenas 谩gua n茫o ajuda, pois n茫o impede que o v铆rus grude na sua m茫o. Assista a este v铆deo para saber como 茅 que o sab茫o elimina o v铆rus   Pergunta: Por que voc锚 deve evitar tocar no seu rosto? Resposta: Isso ocorre porque o v铆rus pode facilmente entrar no corpo pela boca, nariz ou at茅 olhos. No entanto, o v铆rus n茫o entra no seu corpo atrav茅s da pele, pois atua como uma barreira f铆sica. Saiba mais no website CDC.gov   Pergunta: Devo tomar antibi贸ticos para tratar o Covid-19 e os produtos antibacterianos s茫o 煤teis? Resposta: Os antibi贸ticos n茫o s茫o projetados para interromper infec莽玫es virais e, portanto, n茫o s茫o 煤teis ao tentar tratar o Covid-19. Como explicado acima, bact茅rias e v铆rus s茫o dois microorganismos muito diferentes. Isso significa que os produtos antibacterianos tamb茅m n茫o s茫o 煤teis, ao desinfetar superf铆cies do Covid-19. Em vez disso, voc锚 deve usar desinfetante ou 谩lcool.   Pergunta: A capacidade do v铆rus se espalhar 茅 afetada pelo clima? Resposta: At茅 o momento, n茫o h谩 evid锚ncias cient铆ficas para sugerir ou provar que o v铆rus 茅 menos eficaz na propaga莽茫o em clima quente ou 煤mido.   Pergunta: Quais s茫o os sintomas da Covid-19? Resposta: Pessoas com Covid-19 tiveram uma ampla gama de sintomas relatados - desde sintomas leves a doen莽as graves. Os sintomas podem aparecer 2-14 dias ap贸s a exposi莽茫o ao v铆rus. Pessoas com esses sintomas podem ter Covid-19: Febre ou calafrios Tosse Falta de ar ou dificuldade em respirar Fadiga Dores musculares ou corporais Dor de cabe莽a Nova perda de paladar ou olfato Dor de garganta Congest茫o ou coriza N谩usea ou v么mito Diarreia Esta lista n茫o inclui todos os sintomas poss铆veis. O CDC continuar谩 a atualizar esta lista 脿 medida que aprendermos mais sobre o Covid-19. Saiba mais no website CDC.gov   Pergunta: Algu茅m pode testar negativo e posteriormente positivo num teste viral para o Covid-19? Resposta: Sim, 茅 poss铆vel. Voc锚 pode ter um resultado negativo se a amostra foi coletada no in铆cio de sua infe莽茫o e um resultado positivo mais tarde durante esta doen莽a. Voc锚 tamb茅m pode ser exposto ao Covid-19 imune ap贸s o teste e infetado. Mesmo se voc锚 testar negativo, voc锚 ainda deve tomar medidas para proteger a si e aos outros. Consulte Teste para infec莽茫o atual para obter mais informa莽玫es. Saiba mais no website CDC.gov   Pergunta: Se eu me recuperei do Covid-19, estarei imune? Resposta: Ainda n茫o sabemos se as pessoas que se recuperam do Covid-19 de ficar doente com Covid-19 mais de uma vez. At茅 que saibamos mais, continue a tomar medidas para proteger a si e aos outros. Saiba mais no website CDC.gov   Pergunta: Quem est谩 em maior risco de doen莽as graves por causa da Covid-19? Resposta: Covid-19 茅 uma doen莽a nova e h谩 informa莽玫es limitadas sobre fatores de risco para doen莽as graves. Com base nas informa莽玫es dispon铆veis no momento e nos conhecimentos cl铆nicos, idosos e pessoas de qualquer idade com s茅rias condi莽玫es m茅dicas subjacentes podem estar em maior risco de doen莽a grave por causa do Covid-19. Com base no que sabemos agora, aqueles com alto risco de doen莽a grave por Covid-19 s茫o: Pessoas com 65 anos ou mais Pessoas que vivem em um lar de idosos ou em institui莽玫es de longa perman锚ncia Pessoas de todas as idades com condi莽玫es m茅dicas subjacentes, principalmente se n茫o forem bem controladas, incluindo: Pessoas com doen莽a pulmonar cr么nica ou asma moderada a grave Pessoas que t锚m problemas card铆acos graves Pessoas imunol贸gicas   Links 脷teis httpss://www.youtube.com/watch?v=O-3Mlj3MQ_Q&feature=youtu.be httpss://www.youtube.com/watch?v=n6QwnzbRUyA&feature=youtu.be httpss://www.livescience.com/coronavirus-kids-guide.html httpss://www.natgeokids.com/au/discover/science/general-science/what-is-coronavirus/ httpss://www.youtube.com/watch?v=BE-cA4UK07c&feature=youtu.be httpss://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/fulltext httpss://www.wjgnet.com/2307-8960/full/v8/i8/1391.htm   Informa莽茫o Relevante Manual Pr谩tico Colaborador 四色AV - Covid-19 Manual para a Preven莽茫o e Tratamento da Covid-19 WHO-2019-nCoV-IPC - Water, sanitation, hygiene, and waste management for the COVID-19 virus Para desinfectar as superf铆cies a OMS recomenda uma solu莽茫o (mistura) de 0,5% de lix铆via (hipoclorito de s贸dio) em 谩gua. As embalagens de lix铆via para uso dom茅stico indicam a concentra莽茫o em % no r贸tulo - num exemplo do Continente vimos a indica莽茫o de 5% - da铆 que para conseguir ter uma concentra莽茫o para desinfetar as superf铆cies com esse produto a 5% 茅 preciso diluir com mais 脿gua:  a uma medida de lix铆via a 5% juntar 9 medidas de 谩gua para ter uma solu莽茫o a 0,5%. Cuidado com a lix铆via, em concentra莽玫es de 5% ou mais causa queimaduras na pele. Se pingos forem para a pele ou os olhos lave abundantemente com 谩gua durante 2 minutos.   Webinar   Apresenta莽茫o Webinar Resposta a Covid-19 - Partilha de experi锚ncias. Juntos somos mais fortes 16 julho 2020   Prestadores de Servi莽os Prestadores de Servi莽os: Plano de Conting锚ncia COVID-19   Regras de Circula莽茫o em Instala莽玫es 四色AV em Sete Casas e Lumiar   Videos 四色AV - Messagem de 脡lie Vannier, Presidente do Conselho de Administra莽茫o (30 de julho 2020) Legendado em Portugu锚s     ABCovid: Entrevista de Santiago Sampaio no programa Curto Circuito, SIC Radical (13 de julho 2020) Saber mais sobre o Concurso Nacional ABCovid   Mensagem de Ana Cristina Guimar茫es, Diretora de RH Portugal (26 de junho de 2020)   Mensagem de Isabel Jonet, Banco Alimentar Contra a Fome (5 de junho 2020)   Regras de Regresso de Casa (28 de maio de 2020)   Regras de Regresso de Casa - Regra 1   Regras de Regresso de Casa - Regra 2   Regras de Regresso de Casa - Regra 3   Regras de Regresso de Casa - Regra 4 e 5   Regras de Regresso de Casa - Regra 6   Regras de Regresso de Casa - Regra 7 Regras de Regresso de Casa - Regra 8   Regras de Regresso de Casa - Regra 9   Regras de Regresso de Casa - Regra 10   Regras de Regresso de Casa - Regra 11     Hist贸rias de Supera莽茫o (1 de maio de 2020)     Somos a segunda linha de defesa (27 de abril de 2020) Video dispon铆vel com legendas em  CN  |  EN       Mensagem de Filipe Gaspar, Chief Technology Officer (7 de abril de 2020)       Mensagem de Tiago Ferreira de Matos, General Counsel (31 de mar莽o de 2020)       Mensagem de Guy Villax - Lavagem de m茫os (25 de mar莽o de 2020)     Mensagem de Guy Villax a partir da f谩brica de Sete Casas em Portugal (19 de mar莽o de 2020)     Medidas internas coronav铆rus com procedimentos 脿 chegada aos nossos sites (6 de mar莽o de 2020)   Recomenda莽茫o de medidas de prote莽茫o individual e coletiva na preven莽茫o da infe莽茫o com COVID-19 Fonte: DGS, Dire莽茫o-Geral da Sa煤de   Preven莽茫o e Prote莽茫o Fonte: DGS, Dire莽茫o-Geral da Sa煤de     O novo coronav铆rus - COVID-19 Fonte: DGS, Dire莽茫o-Geral da Sa煤de       Empresas alteram produ莽茫o para fabricar desinfetantes Fonte: RTP1         Certifica莽玫es Em resultado de um esfor莽o conjunto entre a 四色AV e a Gertal, as Cantinas de Sete Casas e do Lumiar foram certificadas pela APCER com o selo 鈥淐ovid Safe Verified鈥. 鈥淐ovid Safe鈥 茅 uma marca desenvolvida pela APCER que certifica o cumprimento das novas regras de seguran莽a e sa煤de, no contexto da pandemia da Covid-19. Esta certifica莽茫o 茅 o reconhecimento da preocupa莽茫o da 四色AV e da Gertal em cumprir as regras estabelecidas e em proporcionar as melhores condi莽玫es de seguran莽a aos nossos Colaboradores.   Not铆cias / Media Inspirar 脿 a莽茫o鈥 para uma sa煤de de qualidade (ODS 3) 29 janeiro 2021   ABC Covid-19 (para escolas) A iniciativa ABC Covid-19 visa ajudar as escolas de todo o pa铆s com o regresso 脿s aulas de uma forma pr谩tica, eficaz e direta, dando apoio para enfrentar as dificuldades encontradas no funcionamento di谩rio.  A equipa, composta por estagi谩rios e supervisionada pela equipa de resposta ao Covid-19 da 四色AV, pretende ajudar a informar os alunos dos bons h谩bitos a adotar e como prevenir os riscos, mas tamb茅m dar apoio aos professores e funcion谩rios para que estes tenham acesso a informa莽茫o fidedigna, atualizada e simples. Aqui pode encontrar toda a nossa informa莽茫o em formato PDF para poder utilizar em forma de posters na escola. Posters 01. Uso de M谩scara A / Uso de M谩scara 02. Uso de M谩scara B  03. Retirar a M谩scara 04. Regras para sair de casa 05. Recomenda莽玫es 06. Prote莽茫o Covid-19 07. Lave as m茫os com frequ锚ncia 08. Lavagem de m茫os / Lavagem de m茫os 09. Lavagem de m茫os com gel desinfetante 10. Como medir a temperatura 11. Medidas Gerais 12. Medidas Escolas 13. Utiliza莽茫o de L铆xivia (1) 14. Utiliza莽茫o de L铆xivia (2) 15. Instru莽玫es para Elevadores 16. Distanciamento Social 17. Desinfetar Superf铆cies   Sabe mais em ABCovid.pt Segue-nos nas redes sociais:           Esta certifica莽茫o tem a validade de 6 meses e 茅 renovada ap贸s auditorias de acompanhamento previamente agendadas ou sem aviso pr茅vio.        Aluno de artes de 17 anos da Ant贸nio Arroio vence concurso ABCovid Tom谩s Oliveira, de 17 anos, aluno da Escola Art铆stica Ant贸nio Arroio, em Lisboa, 茅 o vencedor do concurso ABCovid, com o v铆deo 鈥淐ovid-19 simplificado para tot贸s鈥, em que explica de modo simples e gr谩fico porque precisamos de m谩scara para nos protegermos do novo coronav铆rus. O concurso ABCovide 茅 uma iniciativa dos estagi谩rios da 四色AV dirigida a estudantes do ensino b谩sico e secund谩rio. Para mais informa莽玫es visite a p谩gina www.abcovid.pt     

News
Stay updated with the latest information on Covid-19

Covid-19 / Coronavirus

Jul 15, 2022

The Sustainability Report 2019-2020 is聽published under the title 鈥淓lements of the future. For tomorrow and beyond, no matter what.鈥澛 This is the fourth Sustainability Report published by 四色AV and is intended to demonstrate our accountability to our stakeholders by communicating the company's progress on Environmental, Social and Governance (ESG) topics. The Report also reflects our alignment to the United Nations Sustainable Development Goals (UN SDGs).聽 The report has been prepared in line with the Global Reporting Initiative Standards content and quality principles, to ensure information accuracy, clarity and reliability. These standards enable greater transparency and accountability of organizations, by enhancing global comparability and quality of information around ESG performance. The information covers all our owned manufacturing and research facilities worldwide and the data presented is global. As a company, we want to manufacture and deliver medicines of the highest quality to the patients aligned with our commitment to operating a sustainable business. We have as reference the highest standards of safety and environmental performance, staffed by an engaged and diverse workforce. Being 鈥淚n it for life鈥 means that we are committed to protecting our people, our communities, our partners and the environment around us. 聽 Find more about Sustainability at 四色AV 聽

News
The sustainability report covers the fiscal years 2019 and 2020

四色AV releases its 4th Sustainability Report

Jul 14, 2022

On June 29th, at the COTEC Innovation Summit, 四色AV鈥檚 case study, presented in partnership with WeADD, received an honorable mention at the 鈥淚nnovation in Ecosystem鈥 2022 competition. The ceremony took place at the Aveiro Congress Center, and Jo茫o Ventura, Business Director Inhalation Solutions, represented our company. 四色AV was a finalist following a presentation provided together with WeADD, during the COTEC Xperience 4.0 sessions, as part of a collaboration that supports the development of the product 鈥8Shot Dry Powder Inhaler (DPI)鈥. COTEC Portugal is a multisectoral business association that promoted four central axes in this edition of the COTEC Innovation Summit: Industrialization, Sustainability, Knowledge and Competitiveness. 聽 Learn more about our Devices 聽 聽

News
COTEC Innovation Summit

四色AV receives an honorable mention at the 鈥淚nnovation in Ecosystem 2022鈥 competition

Jun 30, 2022

CEFIC (European Chemical Industry Council)聽celebrated its 50th anniversary with the recreation of an iconic photograph dating from 1927. More than 30 Europe鈥檚 top chemistry professors, including two Nobel Prize laureates & 21 PhD students from all across the Europe gathered at the historic setting of the Brussels Metropole Hotel to recreate the iconic 1927Solvay picture featuring Marie Sk艂odowska-Curie and Albert Einstein. Rute Mota, PhD student at 四色AV under the EngIQ Program, was chosen to represent Portugal.聽EngIQ is a successful program that promotes the integration of students in a business environment, co-founded by APQu铆mica of which 四色AV is associated. The original photo included the best European scientists in the field of chemistry at the time and to show continuity a photo was taken this year bringing together some of the most promising PhD students in the field of chemistry at the European level (one per EU Member State). 聽 聽 Learn more about this initiative at CEFIC.org 聽 聽

News
CEFIC remakes the iconic 1927 photo. 34 renowned chemistry professors and 21 young European scientists recreate the iconic photo featuring Curie and Einstein

PhD student represents 四色AV in the iconic photo featuring Curie and Einstein

Jun 28, 2022

Collaboration is key to achieving our climate goals. Together with the Business in the Community Ireland Low Carbon Pledge, we continue to be committed to climate action as part of a movement of 70 businesses. Setting and working towards the achievement of science-based emissions reduction targets, together with peer-to-peer learning and collaboration, are some of the key actions we are taking to transition to a net-zero future. Today the 4th Annual Low Carbon Pledge Report progress report was published sharing the steady progress of our collective movement. Being part of this collective movement is strategic for 四色AV Cork as we are committed to doing our part for a better world. As part of 四色AV鈥檚 commitment to climate action, we are proud to be a Business in the Community Ireland Low Carbon Pledge signatory. The Low Carbon Pledge is the first dedicated pledge generated by Irish businesses to set industry standards on sustainability and reduce carbon emissions. Originally launched in 2018, the Pledge has now evolved and calls on all Irish businesses to work collectively towards setting science-based targets and achieving our long-term climate goals of net-zero by 2050.   You can download a copy of the 4th Annual Low Carbon Pledge Report at BITC.ie   Find more about Sustainability at 四色AV          

News
4th Annual Low Carbon Pledge Report

The Low Carbon Pledge

Jun 23, 2022

In this episode of the Drug Solutions Podcast, Feliza Mirasol, science editor, discusses the changing parameters for oral solid dosage forms as driven by APIs and new chemical entities with Deepak Thassu, vice-president R&D and Regulatory Submission, LGM Pharma, and Marco Gil, senior vice-president of Sales & Marketing, 四色AV. 聽 聽 Oral solid dosage forms are a dynamic, ever-changing landscape, driven primarily by more highly potent new chemical entities (NCEs) that require particularly specific formulations. In this Drug Solutions Podcast episode, Deepak Thassu, vice-president R&D and Regulatory Submission, LGM Pharma, and Marco Gil, senior vice-president of Sales & Marketing, 四色AV, discuss how, in addition to NCEs, older, more established APIs are finding renewed life because these APIs are continually enhanced to have higher potency at lower doses, changing the way their formulation is handled. Looking toward the future, the bio/pharma industry is also tackling the issue of converting large-molecule (biologic) drugs into orally administered dosage, rather than parenteral administration, for increased patient compliance. Among the issues discussed are: The latest developments in oral solid dosage technology and methodologies What remains the biggest challenges in formulating APIs for oral solid dosage administration How the industry is tackling the issue of enhancing bioavailability through better oral solid dosage formulations/technologies, etc. Some 鈥渂est-practice鈥 approaches to formulating oral solid dosage products 聽 You might be interested in: Learning more about our optimal solutions for complex drug products Making聽your drug soluble with Dispersome庐 technology 聽 聽

Article
PharmTech.com, 21 June 2022

Drug Solutions Podcast: The Evolving Landscape of Oral Solid Dosage Forms

Jun 21, 2022

Lisbon, Portugal and Shanghai, China, 9 May 2022 鈥 四色AV, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).聽 JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.聽 鈥淲e are excited to partner with 四色AV and today鈥檚 agreement further strengthens JIXING鈥檚 ophthalmology pipeline beyond its current focus on presbyopia and dry eye disease,鈥 said Peter Fong, PhD, board executive director, JIXING. 鈥淚n addition, this agreement marks a significant step for the company as it highlights its development from a China focused, late clinical-stage biotech to an innovation pioneer with full life cycle development capabilities to reach customers and patients globally.鈥 鈥淲e are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing 四色AV鈥檚 leadership position in spray dried dispersions鈥 said Marco Gil, VP Sales at 四色AV adding 鈥淥ur highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization, offering the best scale-up science, extensive manufacturing capacity and an excellent approval track record.鈥 This Global License Agreement is aligned with 四色AV鈥檚 strategy to offer integrated product solutions for drug delivery that co-create value with its partners and enable the development of innovative medicines that maximize patient benefit.聽 Destum Partners acted as business development and licensing transaction advisor to 四色AV.聽 聽 聽 About JIXING:聽JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients in China with serious and life-threatening diseases. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients in Greater China. For further information about JIXING, please visit www.jixingbio.com聽 聽 About 四色AV:聽四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization聽(CDMO) with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV is the only independent company offering a complete range of services, from API, formulation development and devices. 四色AV is a company with a culture based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. 聽 聽

Press Release
四色AV, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).

四色AV and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

May 09, 2022

四色AV has appointed as CEO its chief operating officer, Jean-Luc Herbeaux, effective April 1. Herbeaux succeeds Guy Villax, who has been CEO of the family-owned pharmaceutical services company for 25 years. Herbeaux joined the firm in 2020. He previously held several management positions at the German chemical maker Evonik Industries, where his final role was head of the health-care business. In November, he and Villax outlined a $170 million investment program through 2023 that they said will increase 四色AV鈥檚 production capacity by about 25%. Villax is credited with moving the company into the exclusive synthesis of active pharmaceutical ingredients (APIs) for drug industry customers. 四色AV, one of several family-owned drug services companies in Europe, saw sales grow by 10 times under Villax鈥檚 stewardship. Major investments included the purchase of a Pfizer plant in Ireland in 2009. Villax says 四色AV鈥檚 board chose to hire a nonfamily CEO in response to growth over the past 5 years. 鈥淲hen a company employs 1,600 or 1,700, you need skills that other people have much more developed than I have,鈥 he tells C&EN. 四色AV has about 2,000 employees. 聽 Read the article on cen.acs.org聽and聽the聽full article (restricted content) 聽 聽 聽

Press Clipping
C&EN, 6 March 2022

四色AV promotes Herbeaux to CEO

Mar 06, 2022

Lisbon, Portugal, 25 February 2022 鈥 四色AV today announced that the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as 四色AV鈥檚 Chief Executive Officer, effective 1st April 2022. 聽 聽 Guy Villax, who has been 四色AV鈥檚 CEO for the past 25 years will now serve as a Member of the Board and shareholder. During his tenure, 四色AV grew tenfold.聽 The company currently employs 2000 team members, serves the global market from four production sites in 3 regions, and is recognized as a leader in its field.聽聽 聽 聽 The Board of Directors expresses its thanks to Guy Villax for his dedication and outstanding achievements. During his career at 四色AV, Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing. 聽 聽 鈥淚t has been a privilege and honor to lead 四色AV over the last decades. 四色AV is a great company because of its people and its clients. It has been an amazing entrepreneurial and human journey with so many projects and unforgettable success stories. I have seen this company, founded by my parents, growing, evolving and constantly re-inventing itself鈥, said Guy Villax. 鈥淒r. Herbeaux joined 四色AV nearly two years ago as COO and from day 1 brought change and contributed to financial and business successes.聽 We have worked together both on the strategy which will take 四色AV to the next level and on making this transition smooth. I am certain that both the company and our Team-Members will continue to thrive under his leadership鈥, added Guy Villax.聽聽 聽 聽 鈥淚 am honored to be entrusted with the role of 四色AV鈥檚 CEO and I am deeply motivated to lead this team of talented professionals. Building on Guy Villax麓s legacy of innovation and customer intimacy, we will continue to work to drive long-term growth for both ourselves and our customers maintaining the 四色AV values. 四色AV puts customers and patients at the center of everything it does and this focus will not change. Our customers can expect us to continue to deliver on what we promise and to offer innovative approaches to their project needs.鈥, said Jean-Luc Herbeaux. 聽 聽 Before joining 四色AV in May 2020, Dr. Herbeaux held multiple high-level leadership positions at Evonik, where he last headed the Health Care Business Line Dr. Herbeaux holds both a Master of Science and a Ph.D. in Mechanical Engineering with a research focus on Rheology from the University of Houston. 聽 聽 聽 About 四色AV: 四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization聽(CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of and services, from API, formulation development and devices. 四色AV was the first Chemical/ Pharmaceutical Company to became a Certified B Corp, is a member of Rx-360, EFCG and participates actively in the industry standard setting process. 聽 聽 聽 聽 聽

Press Release
四色AV today announced the appointment of Dr. Jean-Luc Herbeaux as 四色AV鈥檚 Chief Executive Officer, effective 1st April 2022

Jean-Luc Herbeaux to become 四色AV CEO

Feb 25, 2022

Lisbon, 22nd February 2022 鈥 四色AV, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome庐, Zerion麓s proprietary solubility enhancement technology platform. 聽 Zerion麓s innovative Dispersome庐 technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By combining Dispersome庐 technology with 四色AV鈥檚 unique spray drying capabilities, experience in development, scale-up and GMP manufacturing, 四色AV further strengthens its leadership in amorphous solid dispersions and shows its commitment to innovative solutions to overcome one of the most prevalent challenges faced by the industry: low drug solubility.聽 聽 鈥淲e are extremely pleased to have entered into this partnership with Zerion whom we recognize as a very innovative company in the field of oral drug formulations. By joining forces, Zerion and 四色AV will be able to bring Dispersome庐 to the market faster. We look forward to applying the technology in collaboration with our customers and partners in our effort to develop novel drugs with strong benefits to patients.鈥, comments Jean-Luc Herbeaux, 四色AV麓s Chief Operating Officer. 鈥溗纳獳V will continue to pursue opportunities to enhance its offering around core areas of expertise such as particle engineering and inhalation by partnering with companies and research institutions developing innovative drug formulation technologies, like Dispersome庐鈥. 聽 Zerion麓s CEO, Ole Wiborg, sees a strong synergy in the partnership and expects it to generate new pharma partnerships. 鈥淲e consider 四色AV the global leader in the field of producing amorphous solid dispersions by spray-drying. More importantly for us, this leadership has resulted in 四色AV being, over the last 5 years, the main commercial manufacturer of novel FDA-approved drugs formulated as amorphous solid dispersions. Incorporating these competencies in our offering to the pharma industry both validates the strength of our Dispersome庐 platform and provides us and our pharma partners immediate access to the highest quality in upscaling and commercial GMP manufacturing.鈥 says Ole Wiborg. 聽 The announcement of this partnership follows 四色AV鈥檚 communication on a further expansion with an expected investment of $170 million in assets worldwide and shows the company鈥檚 commitment to also expand its technology platforms. 四色AV is investing both in new assets and innovative technologies to meet customer demand for integrated and differentiated services in drug substance manufacturing, particle engineering and most recently drug product manufacturing. 聽 About 四色AV:聽四色AV is an international company with over 60 years of experience as a聽Contract Development and Manufacturing Organization聽(CDMO)聽with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four聽FDA inspected聽sites聽in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the聽development and compliant manufacture聽of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV is the only independent company offering a complete range of services, from API, formulation development and devices. 四色AV is a company with a culture based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. 聽 About Zerion Pharma ApS: Zerion has pioneered the Dispersome庐 technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic outcomes for the patients. The Dispersome庐 technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin, a sustainable and biodegradable by-product from cheese production. Zerion develops proprietary drug formulations and offers the Dispersome庐 technology to established pharma companies as a means to solve their most challenging drug solubility problems. Zerion was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research. 聽 聽 (Dispersome庐 is a trademark of Zerion Pharma A/S) 聽 聽 Learn more about Dispersome庐 technology 聽

Press Release
四色AV, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome庐, Zerion麓s proprietary solubility enhancement technology platform.

四色AV and Zerion Pharma announce a strategic partnership to market the Dispersome庐 technology platform

Feb 22, 2022

Lisbon, Portugal, 18th February 2022 鈥 四色AV announced today that effective March 1st, or as existing contracts allow, it will increase prices for its Products and Offerings for the global pharmaceutical industry, such as Minocycline, Doxycycline, Ivermectin, Fluticasone, and Mometasone. The necessity of price adjustments stems from increases in the costs of raw materials, labor, energy, transportation, packaging, equipment, and maintenance. Price increases of up to 40% for off-patent Active Pharmaceutical Ingredients and Portfolio Products are required to offset these effects and continue to provide products sustainably to the market. For Development and Manufacturing Services, price increases will be applied to recalibrate the price to cost ratios based on the specific conditions of each program. 四色AV is dedicated to supporting the global pharmaceutical industry and patients around the globe with consistent and reliable supply meeting the most stringent technical, quality, and compliance requirements. We continue to invest in our people, sites, technologies, and products to ensure we meet this commitment. In case you have any questions about these price increases, please contact your account manager. 聽 About 四色AV:聽四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization聽(CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA聽inspected sites聽in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of and services, from API, formulation development and devices. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. 聽

Press Release
News release, 18 February 2022

四色AV increases prices for its off-patent Active Pharmaceutical Ingredients, Portfolio Products as well as Development and Manufacturing Services

Feb 18, 2022

The Mark is operated by Business in the Community Ireland (BITCI), the non-profit organisation dedicated to sustainability and third-party audited by the National Standards Authority of Ireland (NSAI). Seven companies achieved the Mark for the first time with another ten achieving recertification. 聽 聽 聽 Press Release Thursday聽17th聽February:聽 Over 200 business leaders attended Business in the Community Ireland鈥檚 virtual celebration event where the latest companies certified to the Business Working Responsibly mark in 2021/2022 were announced. The Mark which is run by Business in the Community Ireland and based on ISO 26000 is valid for three years and is independently audited by the National Standards Authority of Ireland (NSAI). Seven companies are being accredited to the Mark for the first time this year and they are Alkermes, An Post, Grant Thornton Ireland, Iarnr贸d 脡ireann 鈥 Irish Rail, Ornua, Vermilion and William Fry. In addition, ten companies achieved recertification to the Mark and they are Boots (Retail) Ireland Ltd, BT Ireland, Central Bank of Ireland, CRH Operating Companies in Ireland, Deloitte Ireland, Gas Networks Ireland, HEINEKEN Ireland, 四色AV, Intel Ireland and Sodexo Ireland.聽46 companies in Ireland have now achieved the sustainability standard. The Mark聽 looks at leadership, policies, practices, performance and impact in areas such as employee wellbeing, diversity and inclusion, environmental practices, supply chain management and engagement with the local community. For more details on our sustainability standard,聽visit the Business Working Responsibly mark section of our website.聽 聽 Read the full article on BITC.ie 聽 聽

Press Clipping
BITCI Ireland, 17 February 2022

Seven Companies in Ireland achieve the Business Working Responsibly mark with a further ten recertifying to the standard

Feb 17, 2022

The Portuguese drug services firm 四色AV has outlined a $170 million investment program through 2023 that it says will increase its production capacity by about 25%. In East Windsor, New Jersey, where 四色AV is investing $50 million, the company will add two spray dryers, tripling capacity, and expand its capacity to make research- and small-scale quantities of active pharmaceutical ingredients (APIs). 鈥淲e are looking to build this up to a significant site for 四色AV with more than 300 people,鈥 says Jean-Luc Herbeaux, the firm鈥檚 chief operating officer. 四色AV currently employs about 150 people in New Jersey. In Cork, Ireland, it will spend about $50 million to upgrade its high-potency API production and add a spray dryer. In Loures, Portugal, 四色AV is spending $70 million on additions such as a new manufacturing building and an eight-lab quality control facility. These projects, some of which are already complete, will take up all the available space at the Loures site, according to CEO Guy Villax. 鈥淟ast year we broke $300 million in sales,鈥 Villax says, and the firm is targeting $400 million this year. 鈥淭he company needs to be less Portuguese. You will see us invest and grow our footprint more in the US than elsewhere.鈥漈he Portuguese drug services firm 四色AV has outlined a $170 million investment program through 2023 that it says will increase its production capacity by about 25%. In East Windsor, New Jersey, where 四色AV is investing $50 million, the company will add two spray dryers, tripling capacity, and expand its capacity to make research- and small-scale quantities of active pharmaceutical ingredients (APIs). 鈥淲e are looking to build this up to a significant site for 四色AV with more than 300 people,鈥 says Jean-Luc Herbeaux, the firm鈥檚 chief operating officer. 四色AV currently employs about 150 people in New Jersey. In Cork, Ireland, it will spend about $50 million to upgrade its high-potency API production and add a spray dryer. In Loures, Portugal, 四色AV is spending $70 million on additions such as a new manufacturing building and an eight-lab quality control facility. These projects, some of which are already complete, will take up all the available space at the Loures site, according to CEO Guy Villax. 鈥淟ast year we broke $300 million in sales,鈥 Villax says, and the firm is targeting $400 million this year. 鈥淭he company needs to be less Portuguese. You will see us invest and grow our footprint more in the US than elsewhere.鈥 聽 Read the entire article on CEN.acs.org 聽

Press Clipping
C&EN, 21 November 2021

四色AV will expand 3 pharmaceutical chemistry facilities

Jan 24, 2022

Contact Us

If you would like to learn more about 四色AV, kindly fill in the form below and we will be revert to you soon.